Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00646035 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis
A Phase 3 study of End Stage Renal Disease, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 75
- Enrollment target
- 20
- Study locations
NCT00646035: Completed Phase 3 study of End Stage Renal Disease, sponsored by Abbott.
NCT00646035 is a Phase 3 study of End Stage Renal Disease that has completed, run by Abbott. The registered enrollment target is 75 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00646035, a Phase 3 study of End Stage Renal Disease, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 75 participants
- Enrollment target
- 20
- Study locations
Study Summary
To determine the safety and efficacy of paricalcitol capsules as compared to placebo for treatment of secondary hyperparathyroidism by decreasing serum intact parathyroid hormone levels in end stage renal disease subjects on peritoneal dialysis.
Conditions Studied
Interventions
- DRUG paricalcitol capsules
Study Locations (20)
Ohio
- - Cincinnati
- - Cincinnati
- - Cleveland
Florida
- - Fort Myers
- - Tampa
Illinois
- - Evanston
- - Maywood
Tennessee
- - Memphis
- - Nashville
California
- - Los Angeles
Colorado
- - Denver
District of Columbia
- - Washington D.C.
Georgia
- - Savannah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2002-01 |
| Phase | Phase 3 |
What the finished NCT00646035 record still lists
NCT00646035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (91% lower).
The record links to 1 condition, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which paricalcitol capsules is the first listed.
NCT00646035 names 20 study sites across 15 states, led by Ohio, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00646035 about?
NCT00646035 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis". To determine the safety and efficacy of paricalcitol capsules as compared to placebo for treatment of secondary hyperparathyroidism by decreasing serum intact parathyroid hormone levels in end stage renal disease subjects on peritoneal dialysis.
What is the current status of trial NCT00646035?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 75 participants. The study started on 2002-01.
What conditions does trial NCT00646035 study?
This clinical trial studies the following conditions: End Stage Renal Disease.
What interventions are being tested in trial NCT00646035?
The interventions under investigation include: paricalcitol capsules (DRUG).
Who is sponsoring clinical trial NCT00646035?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00646035 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00646035's enrollment target sits among peer trials
75 42nd of 86 higher than 45 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease
RECRUITING · Phase 3
-
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
RECRUITING · Phase 3
-
Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis
COMPLETED · Phase 3
-
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
COMPLETED · Phase 3
-
Prevention of Kidney Transplant Rejection
COMPLETED · Phase 3
-
An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia